GCP
RVLP

GSA Capital Partners’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

GSA Capital Partners’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38,349
Closed -$125K – 1681
2021
Q1 		$125K Buy
+38,349
New +$158K 0.02% 982

Other funds holding RVLP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

GSA Capital Partners's RVLP Position: Q2 2021 in Review

GSA Capital Partners sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q2 2021, closing a stake of 38,349 shares — an estimated $125K sold.

GSA Capital Partners first reported a position in RVLP in Q1 2021 and held it in 1 quarter. The position peaked at $125K in Q1 2021. 46 funds tracked by Wall St. Rank hold RVLP as of Q2 2021.

  • GSA Capital Partners reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q2 2021 after selling out during the quarter.
  • GSA Capital Partners sold 38,349 RVL Pharmaceuticals plc Ordinary Shares shares in Q2 2021, an estimated $125K.
  • GSA Capital Partners first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q1 2021 and held it in 1 quarter.
  • GSA Capital Partners's RVL Pharmaceuticals plc Ordinary Shares position peaked at $125K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q2 2021.

Based on GSA Capital Partners's 13F filing for Q2 2021, filed 5 Aug 2021.